MONTREAL, CANADA AND GENEVA, SWITZERLAND--(Marketwire - October 22, 2008) - AngioChem, Inc., a clinical-stage biotechnology company dedicated to creating and developing new drugs to treat brain diseases, announced today that its lead product, ANG1005, is safe and well tolerated in patients with brain cancer treated to date. ANG1005 consists of a proprietary peptide vector (Angiopep) that transports drugs across the blood-brain barrier (BBB) conjugated to three molecules of the anti-cancer agent paclitaxel. The results, from ongoing Phase I/2 studies in the US and preclinical vector delivery data, were presented today at the 20th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Geneva, Switzerland).
